Scholarlink

<p>Cervical cancer screening is approaching a&#xa0;transition from a&#xa0;primarily cytology-based approach to a&#xa0;risk-adapted strategy. Future screening algorithms are expected to become more individualized, incorporating not only human papillomavirus (HPV) status but also genotyping, vaccination status, prior findings, and molecular biomarkers. The aim is to more precisely identify individuals at high risk while minimizing unnecessary diagnostic interventions. In parallel, the role of triage strategies will continue to expand. Current approaches—including cytology, HPV genotyping (particularly HPV 16/18), and p16/Ki-67 dual staining—already enable refined management of HPV-positive cases. HPV self-sampling has demonstrated strong potential to reach underscreened populations. As HPV vaccination uptake increases, the epidemiology of cervical disease will change substantially, necessitating adjustments in screening intervals and algorithms. In the long term, cervical cancer screening is expected to evolve toward personalized, risk-based models supported by digital tools and artificial intelligence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perspektiven zum deutschen Zervixkarzinom-Screening

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Sarah Schott,
  • Marion Kiechle

摘要

Cervical cancer screening is approaching a transition from a primarily cytology-based approach to a risk-adapted strategy. Future screening algorithms are expected to become more individualized, incorporating not only human papillomavirus (HPV) status but also genotyping, vaccination status, prior findings, and molecular biomarkers. The aim is to more precisely identify individuals at high risk while minimizing unnecessary diagnostic interventions. In parallel, the role of triage strategies will continue to expand. Current approaches—including cytology, HPV genotyping (particularly HPV 16/18), and p16/Ki-67 dual staining—already enable refined management of HPV-positive cases. HPV self-sampling has demonstrated strong potential to reach underscreened populations. As HPV vaccination uptake increases, the epidemiology of cervical disease will change substantially, necessitating adjustments in screening intervals and algorithms. In the long term, cervical cancer screening is expected to evolve toward personalized, risk-based models supported by digital tools and artificial intelligence.